Who are TNK-tPA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fibrinolytic twice daily, low-dose tenecteplase intravenous thrombolysis, Fibrinolytic once daily, Fibrinolytic therapy, Intravenous rhTNK-tPA, Intra-arterial infusion of Alteplase.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tnk-tpa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

TNK-tPA — Competitive Intelligence Brief

TNK-tPA (TNK-tPA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Thrombolytic. Area: Cardiovascular.

phase 3 Fibrinolytic agent / Thrombolytic Plasminogen / Fibrin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

TNK-tPA (TNK-tPA) — Beijing Tiantan Hospital. TNK-tPA is a genetically engineered tissue plasminogen activator that converts plasminogen to plasmin to dissolve blood clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TNK-tPA TARGET	TNK-tPA	Beijing Tiantan Hospital	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Fibrinolytic twice daily	Fibrinolytic twice daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent	Plasminogen / Fibrin
low-dose tenecteplase intravenous thrombolysis	low-dose tenecteplase intravenous thrombolysis	Southwest Hospital, China	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin
Fibrinolytic once daily	Fibrinolytic once daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Fibrinolytic therapy	Fibrinolytic therapy	All India Institute of Medical Sciences	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Intravenous rhTNK-tPA	Intravenous rhTNK-tPA	Xinqiao Hospital of Chongqing	phase 3	Thrombolytic agent / Fibrinolytic	Plasminogen / Fibrin
Intra-arterial infusion of Alteplase	Intra-arterial infusion of Alteplase	Central Hospital, Nancy, France	phase 3	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Thrombolytic class)

All India Institute of Medical Sciences · 1 drug in this class
Angde Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
Beijing Chao Yang Hospital · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
Life Recovery Systems · 1 drug in this class
Tasly Biopharmaceuticals Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
Thrombolex, Inc. · 1 drug in this class
Tianjin Huanhu Hospital · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TNK-tPA — Competitive Intelligence Brief. https://druglandscape.com/ci/tnk-tpa. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab